We propose to develop a drug conjugate from Hyaluronic acid (HA) biomaterial, which is present in extracellular matrices, the synovial fluid of joints, and Hydroxychloroquine (HCQ), which is being considered for the treatment of COVID-19 but it exhibits some toxicity, the HA-HCQ is expected to show reduced toxicity and enhance efficacy.
